RPTX — Repare Therapeutics Share News
0.000.00%
Last trade - 00:00- $112.94m
- $0.34m
- $53.48m
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Brief: Repare Therapeutics Announces Acquisition Of Polθ ATPase Inhibitor, RP-3467, By Gilead Sciences For Up To $30 Million In Total Consideration
Brief: Repare Signs Support Agreements With Key Shareholders For Xenotherapeutics Deal
Repare Therapeutics Q2 net loss narrows to $16.7 mln
Brief: Repare Therapeutics Enters Exclusive Worldwide Licensing Agreement With Debiopharm For Lunresertib
Repare Therapeutics jumps on cancer drug licensing deal
Brief: Repare Therapeutics - Steve Forte, Executive Vice President And Chief Financial Officer, Appointed As President, Chief Executive Officer And Director
Brief: Repare Therapeutics Q3 EPS USD -0.81
Brief: Repare Therapeutics Announces Phase 1 Data Highlighting Camonsertib In Combination With Radiotherapy
Brief: Repare Therapeutics To Present Data From Phase 1/2 TRESR Clinical Trial Evaluating Camonsertib Monotherapy In Multiple Advanced Solid Tumors Harboring ATM Loss-Of-Function At Esmo Congress 2024
Brief: Repare Therapeutics Q2 EPS USD -0.82
Brief: Repare Therapeutics Says Fast Track Designation Granted By FDA For Combination Treatment For Platinum-Resistant Ovarian Cancer
Brief: Repare Therapeutics Q1 Income From Operations USD 10.816 Million
Brief: Repare Therapeutics & Debiopharm Announce First Patient Dosed In Phase 1/1B Mythic Trial
Brief: Repare Therapeutics Appoints Steven Stein To Its Board Of Directors
Brief: Repare Therapeutics FY EPS USD -2.23
Brief: Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-1664
Brief: Repare Therapeutics To Regain Global Rights To Camonsertib
Brief: Repare Therapeutics Announces Achievement Of $40 Million Roche Clinical Milestone Payment